...OH, ONE MORE THING - PLEASE BOOKMARK US & VISIT DAILY!
Gleison Tibau dropped his appeal over two failed drug tests from USADA, one in-competition and one out, and on Thursday he was officially suspended for two years under the terms of the UFC and USADA anti-doping policy.
Tibau tested positive for erythropoietin (EPO) on tests conducted on October 23 of last year, and the night of his last fight on Nov. 7, where he defeated Abel Trujillo with a submission hold despite no tap from Trujillo. As the out-of-competition test came back with a positive result, his win has been overturned to a loss by the Comissao Atletica Brasileira de MMA (CABMMA), which was the regulatory body for the event in question.
The UFC released a statement Thursday on Tibau's suspension, which runs through Nov. 7, 2017:
"UFC recognizes the two-year sanction issued today to Gleison Tibau by the U.S. Anti-Doping Agency (USADA) for violations of the UFC Anti-Doping Policy. UFC secured the services of USADA, a third-party agency, last year to administer its Anti-Doping Policy to ensure that all athletes compete on an even playing field, free of performance enhancing drugs. UFC supports the issuance of necessary sanctions to maintain a clean sport."
Attention iPhone/iPad users, if you've enjoyed our app in the past and followed us there, or if you've never checked it out, make sure to update to the latest version in the Apple store. We've launched a new look for the app, in line with our recent desktop overhaul. Make sure to check it out! An update to our Android app is on its way soon as well, so Android users keep an eye out for that update soon!
DON'T GO YET... WE SUGGEST THESE MMATORCH ARTICLES, TOO!
Jamie Penick, editor-in-chief
(mmatorcheditor@gmail.com)
STAFF COLUMNISTS: Shawn Ennis - Jason Amadi
Frank Hyden - Rich Hansen
Chris Park - Matt Pelkey
Interested in joining MMATorch's writing team? Send idea for a theme to your column (for Specialist section) or area of interest (i.e. TV Reporter) along with a sample of writing to mmatorch@gmail.com.
